Pegaspargase: A review of clinical studies

Advanced Drug Delivery Reviews

Volumn 55, Issue 10, 2003, Pages 1293-1302

  Graham, Michael L ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acute lymphoblastic leukemia; Antineoplastic agents; Asparaginase; Asparagine; Bacterial proteins; Polyethylene glycols; Remission induction

Indexed keywords

ALLERGIES; CHEMOTHERAPY; COSTS; PATIENT TREATMENT; POLYETHYLENE GLYCOLS;

CLINICAL STUDIES; INTRAMUSCULAR INJECTION;

DRUG INFUSION;

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARTATE AMMONIA LIGASE; BILIRUBIN; DOXORUBICIN; LIPOPROTEIN; MEDAC; METHOTREXATE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC REACTION; AMINO ACID BLOOD LEVEL; ANAPHYLAXIS; ANOREXIA; ANTIBODY PRODUCTION; BLOOD CLOTTING FACTOR DEFICIENCY; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMA; DISORIENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ESCHERICHIA COLI; FATIGUE; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; IMMUNE DEFICIENCY; LETHARGY; LIVER DYSFUNCTION; MITOSIS INHIBITION; MOLECULAR WEIGHT; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREATITIS; PAROTITIS; PECTOBACTERIUM CAROTOVORUM; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; PROTHROMBIN DEFICIENCY; RASH; RECURRENT DISEASE; REMISSION; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; URTICARIA; WEIGHT REDUCTION;

EID: 0042999388     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(03)00110-8     Document Type: Article

References (82)

1. Ortega J.A., Nesbit M.E. Jr., Donaldson M.H., Hittle R.E., Weiner J., Karon M., Hammond D. L-Asparaginase, vincristine and prednisone for induction of first remission in acute lymphoblastic leukemia. Cancer Res. 37:1977;535-540.
2. Jones B., Holland J.F., Glidewell O., Jacquillat C., Weil M., Pochedly C., Sinls L., Chevalier L., Maurer H.M., Koch K., Falkson G. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med. Pediatr. Oncol. 3:1977;387-400.
3. Clavell L.A., Gelber R.D., Cohen H.J., Hitchcock-Bryan S., Cassady J.R., Tarbell N.J., Blattner S.R., Tantravahi R., Leavitt P., Sallan S.E. Four-agent induction and intensive L-asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. New Engl. J. Med. 315:1980;657-663.
4. Amylon M.D., Shuster J., Pullen J., Berard C., Link M.P., Wharam M., Katz J., Yu A., Laver J., Ravindranath Y., Kurtzberg J., Desai S., Camitta B., Murphy S.B. Intensive high-dose L-asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 13:1999;335-342.
5. Schrappe M., Reiter A., Ludwig W., Harbott J., Zimmerman M., Hiddemann W., Niemeyer C., Henze G., Feldges A., Zintl F., Kornhuber B., Ritter J., Welte K., Gadner H., Riehm H. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 95:2000;3310-3322.
6. Hann I., Vora A., Richards S., Hill F., Gibson B., Lilleyman J., Kinsey S., Mitchell C., Eden O.B. Benefit of intensified treatment for all children with acute lymphoblastic leukemia: results from MRC UKALL XI and MRC ALL97 randomized trials. Leukemia. 14:2000;356-363.
7. Ashihara Y., Kono T., Yamazaki S., Inada Y. Modification of E. coli L-asparaginase with polyethylene glycol: disappearance of binding ability to anti-L-asparaginase serum. Biochem. Biophys. Res. Commun. 83:1978;385-391.
8. Park Y.K., Abuchowski A., Davis S., Davis F. Pharmacology of Escherichia coli L-asparaginase polyethylene glycol adduct. Anticancer Res. 1:1981;373-376.
9. Kidd J.G. Regression of transplantable lymphomas induced in vitro by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum or rabbit serum. J. Exp. Med. 98:1953;565-582.
10. Broome J.D. Evidence that L-asparaginase activity of guinea pig serum is responsible for its anti-lymphoma effects. Nature. 191:1961;1114-1115.
11. Clementi A. La desamidation enzymatique de l'asparagine chez les differentes especes animals et la signification physiologique de sa presence dans l organisme. Arch. Int. Physiol. 19:1922;369-398.
12. Mashburn L., Wriston J.C. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch. Biochem. 105:1964;450-452.
13. T. McCoy. et al., cited in J.G. Kidd, L-Asparaginase and cancer - yesterday and today in: E. Grundmann, H.F. Oettgen (Editors), Experimental and Clinical Effects of L-Asparaginase, Springer, New York, 1969, pp. 3-14.
14. Ohnuma T., Holland J.F., Meyer P. Erwinia caratovora L-asparaginase in patients with prior anaphylaxis to L-asparaginase from E. coli. Cancer. 30:1972;376-381.
15. Oettgen R.F., Old L.J., Boyse E.A., Campbell H.A., Philips F.A., Clarkson B.D., Tallal L., Leeper R.D., Schwartz M.K., Kim J.H. Inhibition of leukemia in man by L-asparaginase. Cancer Res. 27:1967;2619-2631.
16. Haskel C.M., Canellos G.P., Leventhal B.G., Carbone P.P., Block J.B., Serpick A.A., Selawry O.S. L-Asparaginase: therapeutic and toxic effects in patients with neoplastic disease. New Engl. J. Med. 281:1969;1028-1034.
17. Ohnuma T., Holland J.F., Freeman A., Sinks L.F. Biochemical and pharmacological studies with L-asparaginase in man. Cancer Res. 30:1970;2297-2305.
18. Capizzi R. Improvement in the therapeutic index of L-asparaginase by methotrexate. Cancer Chemother. Rep. 6:(Part 3):1975;37-41.
19. Lobel J.S., O'Brien R.T., McIntosh S., Aspenes G.T., Capizzi R.L. Methotrexate and L-asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia in childhood. Cancer. 43:1979;1089-1094.
20. Jackson R.D., Handschumacher R.E. Escherichia coli L-asparaginase: catalytic activity and subunit nature. Biochemistry. 9:1970;3585-3590.
21. Maita T., Matsuda G. The primary structure of L-asparaginase from Escherichia coli. Hoppe Seyler's Z Physiol. Chem. 361:1980;105-117.
22. Howard J.B., Carpenter F.H. L-Asparaginase from Erwinia caratovora. Substrate specificity and enzymatic properties. J. Biol. Chem. 247:1972;1020-1030.
23. Kiriyama Y., Kubota M., Takimoto T., Kitoh T., Tanizawa A., Akiyama Y., Mikawa H. Biochemical characterization of 4937 cells resistant to L-asparaginase: the role of asparagine synthetase. Leukemia. 3:1989;294-297.
24. Prager M.D., Bachynsky N. Asparagine synthetase in L-asparaginase resistant and susceptible mouse lymphomas. Biochem Biophys. Res. Commun. 31:1968;43-47.
25. Ueno T., Ontawa K., Mitsui K., Kodera Y., Hiroto M., Matsushima A., Inada Y., Nishimura H. Cell cycle arrest induced by L-asparaginase. Leukemia. 11:1997;1858-1861.
26. Shimizu T., Kubota M., Adachi S., Sano H., Kasai Y., Hashimoto H., Akiyama Y., Mikawa H. Pretreatment of a human T-lymphoblastoid cell line with L-asparaginase reduces etoposide-induced DNA strand breakage and cytotoxicity. Int. J. Cancer. 50:1992;644-648.
27. Fu C., Nandy P., Danenberg P., Avramis V.I. L-Asparaginase (ASNase) induced cytotoxicity depends on the p53 status of the cells. Proc. Am. Assoc. Cancer Res. 39:1998;602.
28. Nandy P., Fu C., Danenberg P., Avramis V.I. Apoptosis induced by antimetabolite taxanes or L-asparaginases in vitro depends on the p53 status of the leukemic cells. Proc. Am. Assoc. Cancer Res. 39:1998;602.
29. Ho D.H., Brown N.S., Yen A., Holmes R., Keating M., Abuchowski A., Newman R.A., Krakoff I.H. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab. Dispos. 14:1986;349-352.
30. Asselin B.L., Whitin J.C., Coppola D.J., Rupp I.P., Sallan S.E., Cohen H.J. Comparative pharmacokinetic studies of three L-asparaginase preparations. J. Clin. Oncol. 11:1993;1780-1786.
31. Albertsen B.K., Jakobsen P., Shroder H., Schmiegelow K., Carlsen N.T. Pharmacokinetics of Erwinia L-asparaginase after intravenous and intramuscular administration. Cancer Chemother. Pharmacol. 48:2001;77-82.
32. Berg S.L., Balis F.M., McCully C.L., Godwin K.S., Poplack D.G. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparaginase concentrations in the rhesus monkey. Cancer Chemother. Pharmacol. 32:1993;310-314.
33. Riccardi R., Holcenberg J.S., Glaubiger D.L., Wood J.H., Poplack D.G. L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 41:1981;4554-4558.
34. Dibenedetto S.P., DeCataldo A., Ragusa R., Meli C., LoNigro L. Levels of L-asparagine in CSF after intramuscular administration of L-asparaginase from Erwinia in children with acute lymphoblastic leukemia. J. Clin. Oncol. 13:1995;339-344.
35. Woo M.H., Hak L.J., Storm M.C., Gajjar A.J., Sandlund J.T., Harrison P.L., Wang B., Pui C.-H., Relling M.V. Cerebrospinal fluid asparagine concentrations after Escherichia coli L-asparaginase in children with acute lymphoblastic leukemia. J. Clin. Oncol. 17:1999;1568-1574.
36. H.F. Oettgen, L-Asparaginase: current status of clinical evaluation, in: A.C. Sartorelli, D.G. John (Editors) Antineoplastic and immunosuppressive agents. H of EP 38/1: A and IA, NY, 1975, SV NY, pp. 229-239.
37. Haskell C.M., Canellos G.P. L-Asparaginase resistance in human leukemia-asparagine synthetase. Biochem. Pharm. 18:1969;2578-2580.
38. Broome J.D., Schwartz J.H. Differences in the production of L-asparagine in L-asparaginase-sensitive and resistant lymphoma cells. Biochim. Biophys. Acta. 138:1967;637-639.
39. Prager M.D., Bachynsky N. Asparagine synthetase in L-asparaginase resistant and susceptible mouse lymphomas. Biochem. Biophys. Res. Commun. 31:1968;43-47.
40. Kirivama Y., Kubota M., Kitoh T., Tanizawa A., Akiyama Y., Mikawa H. Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. Leukemia. 3:1989;294-297.
41. R.G. Hutson, T. Kitoh, D.A. Moraga, Amador, S. Cosic, S.M. Schuster, M.S. Kilberg, Amino acid control of asparagine synthetase: relation to L-asparaginase resistance in human leukemia cells, Am. J. Physiol. 272 (1997) C1691-1699.
42. Cheung N.K., Chay I.Y., Coccia P.F. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am. J. Pediatr. Hematol. Oncol. 8:1986;99-104.
43. Killander D., Dohlwitz A., Engstedt L., Franzen S., Gahrton G., Gullbring B., Holm G., Holmgren A., Hoglund S., Killander A., Lockner D., Melstedt H., Moe P.J., Palmblad J., Reizenstein P., Skarberg K.-O., Swedberg B., Uden A.-M., Wadman B., Wide L., Ahstrom L. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer. 37:1976;220-228.
44. Gentili D., Conter V., Rizzari C., Tschuemperlin B., Zuch M., Orlandoni D., D'Incalci M., Masera G. L-Asparagine depletion in plasma and cerebrospinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann. Oncol. 7:1996;725-730.
45. Woo M.H., Hak L.J., Storm M.C., Sandlund J.T., Ribeiro R.C., Rivera G.K., Rubnitz J.E., Harrison P.L., Wang B., Evans W.E., Pui C.-H., Relling M.V. Hypersensitivity or development of antibodies to L-asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 18:2000;1525-1532.
46. Larson R.A., Fretzin M.H., Dodge R.K., Schiffer C.A. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 12:1998;660-665.
47. Boos J., Werber G., Ahlke E., Schulze-Westhoff P., Nowak-Gottl U., Wurthwein G., Verspohl E.J., Ritter J., Jurgens H. Monitoring of L-asparaginase activity and asparagine levels in children on different L-asparaginase preparations. Eur. J. Cancer. 32A:1996;1544-1550.
48. Package Insert. Oncaspar (pegaspargase). 1994;Rhone-Pooulenc Rorer, Collegeville, PA.
49. Bonno M., Kawaski H., Hori H., Umemoto M., Komada Y., Sakurai M. Rapid desensitization for L-asparaginase hypersensitivity. J. Allergy Clin. Immunol. 101:(Part 1):1998;571-572.
50. Jenkins R., Perlin E. Severe hepatotoxicity from Escherichia coli L-asparaginase. J. Natl. Med. Assoc. 79:1987;775-779.
51. Oettgen H.F., Tallal L., Tan C.C., Murphy M.L., Clarkson B.D., Golbey R.D., Krakoff I.H., Karnofsky D.A., Burchenal J.H. Clinical experience with L-asparaginase. Grundman E., Oettgen H.F. Experimental and Clinical Effects of L-Asparaginase. 1970;219-243 Springer, New York.
52. Homans A.C., Rybak M.E., Baglini R.L., Tiarks C., Steiner M.E., Forman E.N. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J. Clin. Oncol. 5:1987;811-817.
53. Semeraro N., Montemurro P., Giordano P., Schettini F., Santoro N., De Mattia D., Giorano D., Conese M., Colluci M. Unbalanced coagulation- fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukemia. Thromb. Haemost. 64:1990;38-40.
54. Miniero R., Saracco P., Einaudi S., Garofalo L., Lange M.M., Madon E. L-Asparaginase-induced coagulopathy in children with acute lymphoblastic leukemia. Drugs Exptl. Clin. Res. 13:1987;377-379.
55. Shapiro A.D., Clarke S.L., Christian J.M., Odom L.F., Hathaway W.E. Thrombosis in children receiving L-asparaginase. Determining patients at risk. Am. J. Pediatr. Hematol. Oncol. 15:1993;400-405.
56. Nowak-Gottl U., Wolff J.E.A., Kuhn N., Boos J., Kehrel B., Lilienweiss V., Schwabe D., Jurgens H. Enhanced thrombin generation, p-von Willebrand factor, p-fibrin D-dimer and p-plasminogen activator inhibitor 1: predictive for venous thrombosis in L-asparaginase-treated children. Fibrinolysis. 8:(Suppl. 2):1994;63-65.
57. Mitchell L., Hoogendoorn H., Giles A.R., Vegh P., Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood. 83:1994;386-391.
58. Wermes C., von Depka Prondzinski M., Lichtinghagen R., Barthels M., Welte K., Sykora K.-W. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur. J. Pediatr. 158:1999;S143-146.
59. Knofler R., Siegert E., Lauterbach I., Taut-Sack H., Siegert G., Gehrisch S., Muller D., Rupprecht E., Kabus M. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy-impact of central venous lines. Eur. J. Pediatr. 158:1999;5147-5150.
60. Nowak-Gottl U., Wermes C., Junker R., Koch H.G., Schobess R., Fleischhack G., Schwabe D., Ehrenforth S. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant and further prothrombotic risk factors. Blood. 93:1999;1595-1599.
61. Mauz-Korholz C., Junker R., Gobel U., Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli L-asparaginase. Thromb. Haemost. 83:2000;840-843.
62. Sica S., Pagano L., Salutari P., DiMario A., Rutella S., Leone G. Acute parotitis during induction therapy including L-asparaginase in acute lymphoblastic leukemia. Ann. Hematol. 68:1994;91-92.
63. Bertelli A., Donati L., Trabucchi E. Prolonged survival of allo- and xenografts of skin by means of an antitumoral compound; the L-asparaginase. Arch. Ital. Pat. 11:1968;475-479.
64. Burgio G.R., Astaldi A., Krc I., Micu D., Astaldi G. With reference to blastogenesis inhibition by L-asparaginase. Grundman E., Oettgen H.F. Experimental and Clinical Effects of L-asparaginase. 1969;288-295 Springer, New York.
65. Ohno R. Inhibition of lymphocyte blastogenesis by L-asparaginase (LA). Proc. Am. Assoc. Cancer Res. 10:1969;66.
66. Schulten H.K., Giraldo G. Influence of L-asparaginase preparations of E. coli and Agouti serum on the homograft reactivity in the mouse. Grundman E., Oettgen H.F. Experimental and Clinical Effects of L-Asparaginase. 1969;155-159 Springer, New York.
67. Hobik H.P. Immunosuppressive wirkung von L-asparaginase inder graft-versus-host reaction. Naturwissenschaften. 56:1969;217.
68. Fink U., Begemann H. Clinical studies with L-asparaginase in dermatomyositis. Grundman E., Oettgen H.F. Experimental and Clinical Effects of L-Asparaginase. 1969;329-330 Springer, New York.
69. Graham M.L., Asselin B.L., Herndon II J.E., Casey J.R., Chafee S., Ciocci G.H., Wl Daeschner C., Davis A.R., Gold S., Halperin E.D., Laughlin M.J., Martin P.L., Olson J.F., Kurtzberg J. Toxicity, pharmacology and feasibility of administration of Peg-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant. 21:1998;879-885.
70. Taylor C.W., Dorr R.T., Fanta P., Hersh E.M., Salmon S.E. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 47:2001;83-88.
71. Vieira Pinheiro J.P., Muller H.J., Schwabe D., Gunkel M., Casimiro da Palma J., Henze G., von Shutz V., Winkelhorst M., Wurthwein G., Boos J. Drug monitoring of low-dose PEG-L-asparaginase (Oncaspar™) in children with relapsed acute lymphoblastic leukemia. Br. J. Haematol. 113:2001;115-119.
72. Ettinger L.J., Kurtzberg J., Voute P.A., Jurgens H., Halpern S.L. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer. 75:1995;1176-1181.
73. Kurtzberg J., Moore J.O., Scudiery D., Franklin A. A Phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukemias. Proc. Am. Assoc. Cancer Res. 29:1988;213.
74. Douer D., Cohen L.J., Periclou L.A., Watkins K., Levine A.M., Avramis V.I. Peg-L-asparaginase (PEG-ASP): Pharmacokinetics (PK) and clinical response in newly diagnosed adults with acute lymphoblastic leukemia (ALL) treated with multiagent chemotherapy. Blood. 90:(Suppl. 1):1997;334a.
75. Aguayo A., Cortes J., Thomas D., Pierce S., Keating M., Kantarjian H. Combination therapy with methotrexate, vincristine, polyethyleneglycol conjugated-L-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer. 86:1999;1203-1209.
76. Muss H.B., Spell N., Scudiery D., Capizzi R.L., Cooper M.R., Cruz J., Jackson D.V. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs. 8:1990;125-130.
77. Tulpule A., Espina B., Palmer M., Schiflett J., Harvey-Buchanan L., Richards F., Spurr C.L., White P.R., Zekan P.J., Franklin A., Levine A.M. Preliminary results of PEG-L-asparaginase (Oncaspar) in the treatment of relapsed/refractory AIDS-related lymphomas. Blood. 92:(Suppl 1):1998;240.
78. Abshire T.C., Pollock B.H., Billett A.L., Bradley P., Buchanan G.R. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood. 96:2000;1709-1715.
79. Kurtzberg J., Asselin B., Pollack B., Bernstein M., Buchanan G. Peg-L-asparaginase (PEGasp) versus native E. coli L-asparaginase for the reinduction of relapsed acute lymphoblastic leukemia: POG no. 8866 phase II trial. Proc. Am. Soc. Clin. Oncol. 12:1993;325.
80. Holcenberg J., Sencer S., Cohen L.J., Ettinger A., Ettinger L., Gaynon P., Needle M., Mathew P., Sailer S., Sather H., Stork L., Periclou A.P., Avramis V.I. Randomized trial of PEG vs. native-L-asparaginase in children with newly diagnosed acute lymphoblastic leukemia (ALL): CCG study 1962. Blood. 94:1999;628a.
81. Silverman L.B., Gelber R.D., Dalton V.K., Asselin B.L., Barr R.D., Clavell L.A., Hurwitz C.A., Moghrabi A., Samson Y., Schorin M.A., Arkin S., Declerck L., Cohen H.J., Sallan S.E. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium protocol 91-01. Blood. 97:2001;1211-1218.
82. Peters B.G., Goeckner B.J., Ponzillo J.J., Velasquez W.S., Wilson A.L. Pegaspargase versus L-asparaginase in adult ALL: a pharmacokinetic assessment. Formulary. 30:1995;388-393.